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Abstract: Stimulation and release of proinflammatory
cytokines is an essential step for the activation of an
effective innate host defense, and subsequently for the
modulation of adaptive immune responses. Interleukin-1b
(IL-1b) and IL-18 are important proinflammatory cytokines
that on the one hand activate monocytes, macropages,
and neutrophils, and on the other hand induce Th1 and
Th17 adaptive cellular responses. They are secreted as
inactive precursors, and the processing of pro-IL-1b and
pro-IL-18 depends on cleavage by proteases. One of the
most important of these enzymes is caspase-1, which in
turn is activated by several protein platforms called the
inflammasomes. Inflammasome activation differs in vari-
ous cell types, and knock-out mice defective in either
caspase-1 or inflammasome components have an in-
creased susceptibility to several types of infections.
However, in other infections and in models of sterile
inflammation, caspase-1 seems to be less important, and
alternative mechanisms such as neutrophil-derived serine
proteases or proteases released from microbial pathogens
can process and activate IL-1b. In conclusion, IL-1b/IL-18
processing during infection is a complex process in which
the inflammasomes are only one of several activation
mechanisms.
The Role of IL-1b and IL-18 in Host Defense
The main cellular innate host defense mechanisms are the
phagocytosis and killing of bacteria and fungi by neutrophilic
granulocytes, monocytes, and macrophages [1,2], and the lysis of
viral-infected cells by natural killer (NK) cells [3]. Upon
recognition of a microorganism, proinflammatory cytokines such
as tumor necrosis factor (TNF), interferon-c (IFNc), interleukin
(IL)-18, and IL-1b are secreted. These cytokines activate
neutrophils and macrophages to phagocytose the invading
pathogen and to release toxic oxygen and nitrogen radicals.
TNF is an essential component of the host defense, as
demonstrated by the important infectious complications in patients
treated with anti-TNF biological agents [4]. Similarly, IFNc
activates both neutrophils and macrophages for intracellular
killing of bacteria or fungi. Patients with defects in the IL-12/
IFNc activation pathways are at increased risk of severe
mycobacterial and Salmonella infections [5], and recombinant
IFNc is an established therapy in patients with chronic
granulomatous disease [6]. However, in addition to TNF and
IFNc, the proinflammatory cytokines of the IL-1 family, most
notably IL-1b and IL-18, also have very important roles for
antimicrobial host defense. IL-1a and IL-1b, which bind and
activate the same receptor [7], activate the release of other
proinflammatory cytokines such as TNF and IL-6, and induce a
Th17 bias in the cellular adaptive responses [8]. In vivo, IL-1 is
largely responsible for the acute phase response, which includes
fever, acute protein synthesis, anorexia, and somnolence [7], while
IL-18 is essential for the induction of IFNc and Th1 responses [9].
Through these mechanisms, cytokines of the IL-1 family are a
crucial component of the host defense against infections.
IL-1b and IL-18 Processing and Release: The
Inflammasomes
Much interest has been generated regarding the processing and
release of bioactive IL-1b since the discovery of an entire group of
disorders called autoinflammatory syndromes that specifically
respond to the blockade of the IL-1 receptor with the IL-1 receptor
antagonist (IL-1Ra), or with neutralization of IL-1b by the
monoclonal anti-IL-1b antibodies. These syndromes are charac-
terized by attacks of sterile inflammation of joints, serositis, fever,
and skin lesions. Some of the best known diseases in this group
include familial Mediterranean fever (FMF) [10], cryopyrin-
associated periodic syndromes (also known as cryopyrinopathies,
which include familial cold auto-inflammatory syndrome [FCAS]
[11], Muckle-Wells syndrome [MWS] [12], and neonatal onset
multisystem inflammatory disease [NOMID] [13]), hyperimmu-
noglobulin D syndrome (HIDS) [14], TNF receptor–associated
periodic syndrome (TRAPS), and adult-onset Still’s disease [15].
Blood monocytes from patients with some of these disorders,
especially cryopyrinopathies, readily release more IL-1b than
monocytes from unaffected controls, revealing a loss of the tight
control that regulates the processing and release of active IL-1b.
An abnormal production of IL-1b has been therefore proposed to
be the underlying cause of these diseases.
Several mechanisms control the production and activity of
IL-1b, including the processing of the 31-kDa inactive IL-1b
precursor form into the bioactive 17-kDa IL-1b [16], and the
release from secretory lysosomes through K
+-dependent mecha-
nisms [17,18]. In addition, control over IL-1 activity is exerted by
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[19]. Processing of bioactive IL-1b (and that of IL-18) depends on
activation of caspase-1 by protein complexes termed the inflamma-
somes [20]. Several protein platforms/inflammasomes have been
described for the activation of caspase-1, and each of them include
members of the NOD-like receptor (NLR) family of proteins [21].
Through CARD–CARD and pyrin domain–pyrin domain inter-
actions, a large macromolecular complex is formed to represent a
scaffold for the recruitment and activation of pro-caspase-1. It is
believed, yet not proven, that caspase-1 activation in the
inflammasome is induced by the formation of oligomers and
proximity between caspase-1 molecules.
Several major inflammasome complexes that activate caspase-1
have been described to date. The most intensely studied has been
the inflammasome formed by the NLR family member NLRP3,
which forms complexes that include the adapter protein ASC for
the activation of caspase-1 (Figure 1A). Mutations in NLRP3 have
been described in the cryopyrin-associated periodic syndromes
(CAPS; cryopyrin is a name previously used for NLRP3), whereas
specific NLRP-3 polymorphisms have been associated with
Crohn’s disease [22]. A large number of stimuli have been
described to activate the NLRP3 inflammasome: some of them of
bacterial origin (muramyl dipeptide [MDP], bacterial RNA,
double-stranded RNA), some of them are danger-associated
molecular patterns (uric acid crystals, amyloid-b), but also
exogenous compounds such as asbestos, silica, or alum adjuvant
[23–27]. The precise mechanism leading to the activation of the
NLRP3 is still unclear. The diverse molecular structure of these
compounds most likely precludes the direct stimulation of the
NLRP3 inflammasome. A unifying hypothesis proposes that
common intracellular activities such as induction of hypokalemia,
reactive oxygen species, or calcium-dependent phospholipase 2 are
indirectly activating the inflammasome [28]. However, stimulation
of cells solely with ATP, a known inducer of potassium efflux
through P2X7-mediated mechanisms, is unable to activate
caspase-1, and cell priming with lipopolysaccharide (LPS) is
necessary for ATP to induce inflammasome activation. In this
context, induction of NF-kB-dependent transcription of NLRP3
by Toll-like receptor (TLR) ligands [29] or proinflammatory
cytokines [30] seems to be the critical checkpoint needed for cell
priming prior to inflammasome activation by ATP. In addition,
formation of pores by pannexin-1 is one mechanism through
Figure 1. The prototypical NLRP3 and NLRC4 inflammasomes. (A) The NLRP3 inflammasome is activated by both bacterial (e.g., MDP,
bacterial RNA, b-glucan), exogenous (e.g., silica, alum), and endogenous (e.g., uric acid cristals, ATP) stimuli. (B) The NLRC4 inflammasome is activated
by flagellin in a TLR5-independent fashion.
doi:10.1371/journal.ppat.1000661.g001
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cytoplasm to activate the inflammasome [31].
The only inflammasome that has been reconstituted biochem-
ically is the NLRP1 inflammasome. A study using purified
NLRP1, ASC, and caspase-1 has shown that NLPR1 forms
oligomers in the presence of MDP [32]. However, no evidence has
been presented that MDP can actually bind NLRP1, although
another study suggested the involvement of NOD2/NLRP1
complexes in this process [33]. NLRP-1 polymorphisms have
been associated with vitiligo and autoimmune diseases [34].
In addition to the NLRPs, another NLR member, NLRC4/
IPAF, forms an inflammasome that activates caspase-1 in response
to intracellular flagellin in an ASC-independent manner [35,36].
Caspase-1 activation by flagellin/NLRC4 is independent of TLR5,
suggesting that flagellin recognition is mediated by two systems:
extracellular sensing by TLR5, and intracytoplasmatic sensing by
NLRC4 (Figure 1B). Finally, a newly described mechanism
involving recognition of bacterial DNA by the intracellular sensor
AIM2 suggests the existence of a specific inflammasome complex
that inducescaspase-1activation upon sensing nucleicacids[37,38].
This is a particularly important finding, as intracellular detection of
DNA from invading pathogens is likely to be central for an effective
host defense. AIM2-dependent activation of IL-1b has been
suggested to be critical for the activation of host defense against
vaccinia virus and Francisella tularensis [37], and it is to be expected
that similar effects will be identified in the future for other
pathogens.
Through these studies on the structure and function of
the various inflammasomes, a dogma has emerged during the
last few years in which production and release of IL-1b and IL-18
is the result of two independent signals: one signal is induced
through pattern recognition receptors ( e.g., TLRs) to activate
transcription of pro-IL-1b and pro-IL-18, and one signal is
mediated by the NLR-containing inflammasomes (and indepen-
dent of the TLRs) that induce cleavage of cytokine precursors
into the active IL-1b and IL-18 forms through caspase-1
activation.
Differential Role of the Inflammasome in
Monocytes and Macrophages
Despite the progress made in understanding the process of
IL-1b synthesis, controversy surrounded the capacity of TLR
ligands such as LPS to activate caspase-1 and cause the release of
active IL-1b. By using transfected cell lines and/or NLRP3 knock-
out mice, a broad panel of exogenous and endogenous stimuli
have been proposed to activate the NLRP3 inflammasome (see
above), but purified TLR ligands such as LPS were not among
these inflammasome stimuli. Therefore, based on defective
responses of the monocyte-like leukemia cell line THP-1 to LPS
stimulation, a concept has arisen that IL-1b production induced
by LPS is due to contamination with non-LPS ligands such as
peptidoglycans [23], while LPS by itself is ineffective as a
stimulator of IL-1b release. A second signal, such as MDP or
ATP, is required, and this would induce activation of caspase-1
followed by IL-1b processing and release [39]. However, this
model is derived from data in THP-1 cells [23] and in primary
mouse macrophages [31], and it is inconsistent with many studies
showing abundant production and release of IL-1b from blood
monocytes by TLR ligands such as purified LPS, lipopeptides, and
lipoteichoic acid, as well as cytokines such as TNFa and IL-1 itself
[40,41]. In addition, several studies reported that synthetic
products, which exclude contamination with NLRP1 or NLRP3
ligands, stimulate IL-1b release [42,43].
These apparent discrepancies have been resolved by a study from
ourgroup showingthat synthesisandreleaseofIL-1bdifferbetween
human monocytes and macrophages. Monocytes have constitutive-
ly activated caspase-1, leading to release of active IL-1b after a
single stimulation event with bacterial ligands such as LPS, whereas
macrophages (and THP-1 cells) need two distinct stimuli: one
stimulus induces transcription and translation, and a second
stimulus is needed for caspase-1 activation with subsequent IL-1b
processing and secretion [44] (Figure 2). Although caspase-1 is
constitutively activated in human monocytes, that is still dependent
on inflammasome components, as the inhibition of ASC by siRNA
results in a significant reduction of both caspase-1 activation and
processing of IL-1b [44]. A crucial functional aspect in relation to
the constitutive inflammasome activation in monocytes relates to
the release of endogenous ATP by monocytes. Endogenous ATP
from monocytescaninturn activatetheNLRP3inflammasome and
induce IL-1b secretion through P2X7. In contrast, macrophages
completely lack the capacity to release ATP [45].
Consistent with the failure of in vitro–differentiated macrophages
to release IL-1b is the long known defect in IL-1b synthesis of the
alveolar macrophages. Wewers and colleagues proposed a post-
transcriptional defect in freshly obtained alveolar macrophages
[46]. Recently, they reported differences in pyrin expression
between monocytes and macrophages, and suggested that pyrin
induces IL-1b release [47]. Monocytes from patients with FMF who
have mutations in pyrin release more IL-1b upon stimulation than
cells from control subjects, suggesting a failure to suppress the
activation of caspase-1 [10].
These data imply a paradigm shift in our understanding of the
inflammasome. The demonstration of a role for ASC and NLRP3
in the constitutive activation of caspase-1, independent of
stimulation by TLRs or inflammasome ligands, uncouples
caspase-1 activation from pathogen-associated molecular pattern
(PAMP) recognition in human primary monocytes. This new
model, in which the inflammasome components ASC and NLRP3
form a protein platform responsible for the constitutive activation
of caspase-1, explains why IL-1b induction in monocytes by a very
diverse panel of stimuli (including TLR ligands) is caspase-1
dependent, although these stimuli need not themselves be involved
in inflammasome activation. In addition, a role of ASC and
NLRP3 in caspase-1 activation in the monocyte, independently of
‘‘classical’’ inflammasome stimuli, explains the resistance to
experimental endotoxemia in ASC2/2 and NLRP-32/2 mice
[48,49]. In contrast, macrophages need two signals in order to
produce IL-1b, in a model close to the current concept in the
literature: one signal is mediated by TLRs to induce gene
transcription, and a second signal to induce inflammasome
activation for the processing of IL-1b.
The single (TLR ligand only) stimulation in monocytes
compared with the double (TLR ligand/ATP) stimulation in
macrophages (Figure 2) likely represents an adaptation of each cell
type to their respective environments. Circulating monocytes
function in the surveillance of an essentially pathogen-free
environment, so they must respond promptly to any danger signal
(especially of microbial origin). On the other hand, macrophages
are confined to an environment (e.g., alveolar space, mucosal
surfaces) in which they are constantly exposed to (colonizing)
microbial stimuli. An easily inducible response of macrophages to
release IL-1b for each encounter with such exogenous stimuli
would result in chronic deleterious inflammatory reactions. Thus,
repeated bouts of inflammation are likely reduced by the
requirement of a second stimulus for the activation of the
inflammasome and release of active IL-1b. Such second stimuli
would be available at sites of infection, trauma, or necrosis where
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addition, second signals can come from the cathelicidin-derived
peptide LL37 from infiltrating neutrophils [51], or the release of
bacterial toxins [25]. One situation in which caspase-1 activa-
tion seems to be constitutively activated also in macrophages is
represented by the absence of the autophagy gene ATG16L1,
although the precise mechanism responsible for this effect is not yet
elucidated [52]. However, the association of ATG16L1 polymor-
phisms with Crohn’s disease makes this aspect potentially important
for the pathophysiology of this important disease [53,54].
Figure 2. Diagram representing the differential caspase-1/IL-1b activation pathways in monocytes and macrophages. Caspase-1 is
constitutively activated in monocytes, and these cells release mature IL-1b after single stimulation with TLR ligands. IL-1b secretion is induced by
endogenously-released ATP. In contrast, macrophages need a double stimulation: one stimulus (TLR-ligands) induces transcription, and a second
stimulus (ATP) induces IL-1b secretion.
doi:10.1371/journal.ppat.1000661.g002
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Antimicrobial Host Defense
Due to their role in the processing of IL-1b and IL-18, caspase-1
and the inflammasome components are bound to have important
roles in the host defense against pathogenic microorganisms. In vitro
studies have shown that Bacillus anthracis toxin activates IL-1b through
the Nalp1b inflammasome in the mouse [55]. Similarly, NLRP3
activation of caspase-1 has been linked to a variety of microorganisms
ranging from the bacteria Listeria monocytogenes [56,57] and Staphylo-
coccus aureus [58] to viruses such as influenza, adenoviruses, and
Sendai virus [59]. The interaction of NLRC4 with microorganisms
was probably one of the best characterized, demonstrating the
involvement of NLRC4 (independently of ASC) in the activation of
caspase-1 by Salmonella typhimurium [35,36,48], Legionella pneumophila
[60], Pseudomonas aeruginosa [61,62], and Shigella flexneri [63].
In vivo experimental models of infection have also demonstrated
that the lack of caspase-1 in knock-out mice leads to an increased
susceptibility to a variety of infections, including those with F.
tularensis [64], L. pneumophila [65], Shigella [63], Salmonella [66,67],
and P. aeruginosa [62] (Table 1). What all of these infections have in
common is that caspase-1 activity, and thus IL-1b production, is
dependent on the assembly of an inflammasome complex [20],
although they may differ in their specific inflammasome compo-
nents. Experimental infections with some of these pathogens have
been also investigated in knock-out mice lacking components of the
inflammasome. In this respect, ASC-deficient mice have been
shown to be more susceptible to infections with some bacteria
(Francisella and Staphylococcus) [64,68], as well as to influenza viruses
[69], demonstrating its importance in host defense mechanisms. As
in some models ASC2/2 mice are clearly more susceptible to
infections than NLRP32/2 mice (e.g., influenza [69]), one may
suggest a more important role for ASC in antimicrobial defense.
Alternatively, the partial redundancy between different NLRs may
explain the more pronounced phenotype of ASC knock-out mice
compared to single NLR-deficient mice.
Inflammasome-Independent IL-1b Activation
Despite the importance of inflammasome activation in certain
experimental models of inflammation, certain in vivo infection
models in mice deficient in inflammasome components show
intriguing results that question the importance of the inflamma-
some (Table 1). One category of results shows that although
IL-1b is definitely important for inflammatory reactions in
antimicrobial defense, components of the inflammasome or even
caspase-1 can be dispensable. In models of sterile inflammation
induced by turpentine, IL-1b2/2 mice are protected against
inflammation, while caspase-12/2 mice are not [70,71]. This is
in clear contrast with LPS models in which caspase-12/2
mice are protected (Table 1) [72,73]. It appears therefore that
caspase-1 and inflammasome activation is important in some, but
not all, types of IL-1b-driven inflammation [74]. Furthermore,
caspase-1 seems not to be involved in the host defense against
certain types of microorganisms such as Chlamydia trachomatis
[75,76], although IL-1b is involved in the inflammatory responses
induced by these microorganisms [77]. These data argue for
inflammasome-independent activation of IL-1b in certain infec-
tious processes.
An interesting case regarding the involvement of the inflamma-
some in host defense is represented by the fungal pathogen Candida
albicans. IL-1 plays an important role for the host defense and
survival of mice during disseminated candidiasis [75,85]. Surpris-
ingly, caspase-1-deficient mice have been reported to have a
normal resistance to disseminated candidiasis [78], suggesting
activation of IL-1b by alternative mechanisms (see below).
However, NLRP32/2 and ASC2/2 mice have been reported
to be more susceptible to both systemic [79] and mucosal [80]
Candida infections, opening the intriguing possibility of biological
functions of inflammasome components that are not related to
caspase-1 activation. Indeed, an earlier study on the function of
ASC has reported its interaction with NF-kB and an influence on
gene transcription [81]. Whether ASC or NLRP3 have underes-
timated roles that are independent of inflammasome activation
remains to be studied. These studies have shown a role of
inflammasome components in experimental models of Candida
infection in mice, and in line with this the activation of IL-1b in
human monocytes is dependent on caspase-1. However, in
contrast to mouse macrophages, caspase-1 is constitutively
activated in human monocytes and thus does not need fungal
recognition by the NLRs in the inflammasome [82].
Table 1. Susceptibility to In Vivo Experimental Models of Infection in Mice Deficient in IL-1b, IL-18, or Inflammasome Components.
IL-1b2/2 IL-182/2 Caspase-12/2 NLRP32/2 ASC2/2 NLRC42/2
Endotoxemia Normal [74] Lower [95,96] Lower [72,73] Lower [49] Lower [48,49] ND
Turpentine Lower [71,74] ND Normal [70] ND ND ND
E. coli Normal [97] Normal [97] Higher [98]; Lower [97] ND ND ND
Shigella Higher [99] Higher [99] Higher [99] ND ND ND
Salmonella Higher [66] Higher [66] Higher [66] Normal [67] Normal [67] Normal [67]
C. albicans Higher [77,87] Higher [100] Normal [78]; Higher [80] Higher [79,80] ND ND
S. aureus Higher [68] Higher [101] ND ND Higher [68] ND
C. trachomatis ND Normal [102] Normal [76,102] ND ND ND
Listeria Normal [103] Lower [104] Higher [105] ND ND ND
Francisella ND ND Higher [64] ND Higher [64] ND
Legionella ND ND Higher [106] ND ND Higher [60,106]
Influenza Higher [69] Lower [107]; Higher [108] Higher [69] Normal [69] Higher [69] ND
Lower (susceptibility): increased survival of the knock-out mice in the experimental model.
Higher (susceptibility): decreased survival of the knock-out mice in the experimental model.
ND, not done.
doi:10.1371/journal.ppat.1000661.t001
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Shortly after the discovery of IL-1b, when it was apparent that
cleavage of the pro-cytokine is needed for activation, a question
arose as to whether other enzymes apart from caspase-1 would
also be capable of processing pro-IL-1b. Indeed, subsequent
studies have identified neutrophil- and macrophage-derived serine
proteases such as proteinase-3 (PR3), elastase, and cathepsin-G as
enzymes that can process pro-IL-1b into 21-kDa active fragments
[7,83]. Similarly, processing of pro-IL-18 by PR3 can also lead to
active fragments [84]. The crucial role played by neutrophil-
dependent, inflammasome-independent activation of pro-IL-1b
has been elegantly confirmed recently by the group of Greten and
colleagues [85] (Figure 3).
The inflammasome-independent activation of pro-IL-1b in
situations when neutrophils are the major cell population in the
inflammatory infiltrate can explain many of the apparently
puzzling observations reviewed above. It is the neutrophils that
form the backbone of the inflammatory infiltrates during
disseminated candidiasis [86], and this explains the dependency
of host defense against Candida on IL-1b [87], most likely activated
by neutrophil-derived PR3, rather than caspase-1 [78]. Similarly,
inflammatory infiltrates during arthritis consist of both macro-
phages and neutrophils. Indeed, we have observed a minimal role
of caspase-1 during the acute inflammation of arthritis that is
characterized by an overwhelming neutrophil infiltrate. In this
phase of the inflammation, serine proteases such as PR3 played a
more important role [88]. In contrast, during the chronic phase of
inflammation when macrophages are the main component of the
infiltrate, caspase-1 seems to have a more significant effect [88].
Neutrophil-derived serine proteases are not the only alternative
mechanism of activation of pro-IL-1b. One very interesting
phenomenon has recently been reported during infection with C.
albicans, in which a fungus-derived protease can lead to processing
and activation of host-derived pro-IL-1b and thus activation of the
immune system [89]. This may represent an indirect pathway of
Candida recognition by the innate immune system (Figure 3),
reminiscent of the detection of the fungus Beauveria bassiana in
Drosophila through maturation of the protease Persephone by a
fungal-derived enzyme, leading to Toll activation [90]. Consider-
ing the production of a vast array of proteases by practically all
pathogenic microorganisms, it is to be expected that similar IL-1b
activation pathways are active during other infections.
Conclusions and Perspectives: IL-1b Processing
beyond the Inflammasomes
A wealth of information regarding the mechanisms of pathogen
recognition and activation of innate immunity has been accumu-
lated during the last few years, and has contributed greatly to a
better understanding of the host defense against pathogenic
microorganisms. One of the most exciting areas of advancement
was represented by the description of the inflammasomes and the
mechanisms that lead to the processing and activation of cytokines
of the IL-1 family.
There is no doubt that these discoveries have contributed to
a better understanding of inflammatory processes. Beautifully
designed studies have also shown that caspase-1-dependent
mechanisms of IL-1b and IL-18 activation have important
consequences during inflammation. However, as this review has
tried to bring to light, the role played by the inflammasomes
should not deter the acknowledgement of other mechanisms
leading to IL-1b processing that may be just as important.
As shown above, inflammasome activation is not the same in all
cell types, and caspase-1 activation is not the only mechanism
leading to the processing of pro-IL-1b into active fragments.
Neutrophil-derived serine proteases and pathogen-released en-
zymes can also process and activate IL-1b, and these processes
have important effects during inflammation and infection. Further
characterization of these alternative mechanisms can lead to the
Figure 3. Inflammasome-independent processing of pro-IL-1b. In addition to caspase-1-dependent activation, pro-IL-1b can also be
processed by neutrophil-derived serine proteases, or pathogen-derived proteases.
doi:10.1371/journal.ppat.1000661.g003
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inflammatory condition in which neutrophils are involved (e.g.,
rheumatoid arthritis, Crohn’s disease, or gout) is unlikely to
respond to caspase-1 inhibition alone, and a combination of
caspase-1 and PR3 inactivation may be necessary. Beneficial
therapeutic effects of the IL-1 receptor antagonist (IL-1Ra,
anakinra) have often been presented as proof-of-principle for a
role of the inflammasome in certain clinical conditions such as
gout [91,92], in which neutrophils play a crucial role [93]. This
assumption is clearly too preliminary: IL-1Ra will block the effects
of IL-1b irrespective of the mechanisms that led to its activation,
apart from the fact that IL-1a effects are also blocked.
A similar generalization based on IL-1Ra effects is currently the
dogma regarding the pathophysiology of autoinflammatory
syndromes: many of the autoinflammatory syndromes are
considered defects of inflammasome activation. While this is likely
the case for some diseases, for example CAPS, in which NLRP3
mutations are the cause of the disease [94], this relation is much
less clear in other autoinflammatory disorders. It is better to
consider the disorders in which anakinra is active as ‘‘IL-1Ra
responsive diseases’’ or perhaps ‘‘IL-1 related diseases’’ instead of
immediately considering them ‘‘inflammasome-related diseases’’.
While caspase-1 is an obvious candidate to be investigated,
neglecting to investigate other IL-1b-activating mechanisms (or
IL-1a secretion) would be an oversight.
To conclude, the description of the inflammasomes has taught
us a lot, but we should not fall in the trap of our own success.
Caspase-1 activation is just one of the mechanisms of activation of
one of the two active IL-1 molecules, and it is unlikely that an
entire class of PAMP recognition receptors (the NLR receptors)
have evolved only to be devoted to a single immunological
function. While acknowledging the importance of the inflamma-
somes for our understanding of inflammatory reactions, we should
consider in our endeavors the alternative pathways of IL-1b/IL-18
activation, and also actively examine alternative roles of the NLR
class of receptors.
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